Diabetes: Fractyl raises $40M, touts positive early results for ablation-based diabetes therapy

Fractyl closes a $40 million Series C funding round and reveals positive early results for its Revita ablation system in helping control HbA1c levels in patients with type 2 diabetes.

Massachusetts medical device maker Fractyl announced this week that it raised $40 million in support of its ablation-based approach to type 2 diabetes, which looks promising in early studies.

Fractyl

News Well, Clinical Trials, Ablation, Diabetes, Funding Roundup

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1lLVT92